MediWoundMDWD +2.19%56 Days Inventory is 351.10 as of Mar. 2026, which is 508% above its 10-year median of 57.78. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 635 Biotechnology companies, MediWound ranks better than 62.83% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). MediWound's Average Total Inventories for the
three
months ended in Mar. 2026 was $4.43 Mil. MediWound's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $1.15 Mil.
Hence, MediWound's Days Inventory for the
three
months ended in Mar. 2026 was 351.10.
The historical rank and industry rank for MediWound's Days Inventory or its related term are showing as below:
MDWD'
s Days Inventory Range Over the Past 10 Years
Min: 31.41 Med: 57.78 Max: 315.73
Current: 129.78
During the past 13 years, MediWound's highest Days Inventory was 315.73. The lowest was 31.41. And the median was 57.78.
MDWD's Days Inventory is ranked better than 62.83% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs MDWD: 129.78
MediWound's Days Inventory
increased
from Mar. 2025 (88.95) to Mar. 2026 (351.10).
It might indicate that MediWound's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
MediWound's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.26.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MediWound's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 3.01.
MediWound (NAS:MDWD) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
MediWound's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MediWound's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
MediWound Days Inventory Related Terms
MediWound Days Inventory Historical Data
* Premium members only.
The historical data trend for MediWound's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDWD vs UNCY, ARCT, NGEN: Days Inventory Comparison
For the Biotechnology subindustry, MediWound's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Days Inventory distribution charts can be found below:
* The bar in red indicates where MediWound's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a Days Inventory of 351.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on MediWound and its competitors. This is 508% above median its historical median of 57.78. Over the past decade, MediWound's Days Inventory has ranged from 31.41 to 315.73. According to the industry distribution chart, MediWound ranks #236 out of 635 companies in the Biotechnology industry, placing it in the top 37.2%.
Is MediWound's Days Inventory too high?
MediWound's current Days Inventory of 351.10 is 508% above median its 10-year median of 57.78. Over the past 10 years, this metric has ranged from a low of 31.41 to a high of 315.73. The Biotechnology industry median Days Inventory is 183.23. MediWound's value of 351.10 is 91.6% above this industry median. Based on the distribution chart, MediWound ranks #236 out of 635 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Days Inventory compare to UNCY and ARCT?
According to the Biotechnology industry distribution chart, MediWound ranks #236 out of 635 companies for Days Inventory. This puts MediWound in the upper half of its industry. The industry median Days Inventory is 183.23. MediWound's value of 351.10 is 91.6% above this benchmark. Historically, MediWound's own Days Inventory has ranged from 31.41 to 315.73 over the past decade. While the company's 10-year median is 57.78 vs. the industry median of 183.23, MediWound has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediWound's current Days Inventory of 351.10 is 91.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on MediWound and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Days Inventory is 351.10, which is 508% above median its own 10-year median of 57.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Days Inventory is 351.10, which is 508% above median its 10-year median of 57.78 and 91.6% above the Biotechnology industry median of 183.23. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For MediWound (MDWD), the current Days Inventory is 351.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44.
GuruFocus considers MediWound to be Modestly Overvalued.
Key valuation signals for MDWD:
Days Inventory: 351.10 (508% above median its 10-year median of 57.78)
GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
Industry Position: 91.6% above the Biotechnology median (#236 of 635)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score
Get the complete analysis for MDWD
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
